Cargando…

CRI iAtlas: an interactive portal for immuno-oncology research

The Cancer Research Institute (CRI) iAtlas is an interactive web platform for data exploration and discovery in the context of tumors and their interactions with the immune microenvironment. iAtlas allows researchers to study immune response characterizations and patterns for individual tumor types,...

Descripción completa

Detalles Bibliográficos
Autores principales: Eddy, James A., Thorsson, Vésteinn, Lamb, Andrew E., Gibbs, David L., Heimann, Carolina, Yu, Jia Xin, Chung, Verena, Chae, Yooree, Dang, Kristen, Vincent, Benjamin G., Shmulevich, Ilya, Guinney, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658727/
https://www.ncbi.nlm.nih.gov/pubmed/33214875
http://dx.doi.org/10.12688/f1000research.25141.1
_version_ 1783608732824895488
author Eddy, James A.
Thorsson, Vésteinn
Lamb, Andrew E.
Gibbs, David L.
Heimann, Carolina
Yu, Jia Xin
Chung, Verena
Chae, Yooree
Dang, Kristen
Vincent, Benjamin G.
Shmulevich, Ilya
Guinney, Justin
author_facet Eddy, James A.
Thorsson, Vésteinn
Lamb, Andrew E.
Gibbs, David L.
Heimann, Carolina
Yu, Jia Xin
Chung, Verena
Chae, Yooree
Dang, Kristen
Vincent, Benjamin G.
Shmulevich, Ilya
Guinney, Justin
author_sort Eddy, James A.
collection PubMed
description The Cancer Research Institute (CRI) iAtlas is an interactive web platform for data exploration and discovery in the context of tumors and their interactions with the immune microenvironment. iAtlas allows researchers to study immune response characterizations and patterns for individual tumor types, tumor subtypes, and immune subtypes. iAtlas supports computation and visualization of correlations and statistics among features related to the tumor microenvironment, cell composition, immune expression signatures, tumor mutation burden, cancer driver mutations, adaptive cell clonality, patient survival, expression of key immunomodulators, and tumor infiltrating lymphocyte (TIL) spatial maps. iAtlas was launched to accompany the release of the TCGA PanCancer Atlas and has since been expanded to include new capabilities such as (1) user-defined loading of sample cohorts, (2) a tool for classifying expression data into immune subtypes, and (3) integration of TIL mapping from digital pathology images. We expect that the CRI iAtlas will accelerate discovery and improve patient outcomes by providing researchers access to standardized immunogenomics data to better understand the tumor immune microenvironment and its impact on patient responses to immunotherapy.
format Online
Article
Text
id pubmed-7658727
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-76587272020-11-18 CRI iAtlas: an interactive portal for immuno-oncology research Eddy, James A. Thorsson, Vésteinn Lamb, Andrew E. Gibbs, David L. Heimann, Carolina Yu, Jia Xin Chung, Verena Chae, Yooree Dang, Kristen Vincent, Benjamin G. Shmulevich, Ilya Guinney, Justin F1000Res Software Tool Article The Cancer Research Institute (CRI) iAtlas is an interactive web platform for data exploration and discovery in the context of tumors and their interactions with the immune microenvironment. iAtlas allows researchers to study immune response characterizations and patterns for individual tumor types, tumor subtypes, and immune subtypes. iAtlas supports computation and visualization of correlations and statistics among features related to the tumor microenvironment, cell composition, immune expression signatures, tumor mutation burden, cancer driver mutations, adaptive cell clonality, patient survival, expression of key immunomodulators, and tumor infiltrating lymphocyte (TIL) spatial maps. iAtlas was launched to accompany the release of the TCGA PanCancer Atlas and has since been expanded to include new capabilities such as (1) user-defined loading of sample cohorts, (2) a tool for classifying expression data into immune subtypes, and (3) integration of TIL mapping from digital pathology images. We expect that the CRI iAtlas will accelerate discovery and improve patient outcomes by providing researchers access to standardized immunogenomics data to better understand the tumor immune microenvironment and its impact on patient responses to immunotherapy. F1000 Research Limited 2020-08-24 /pmc/articles/PMC7658727/ /pubmed/33214875 http://dx.doi.org/10.12688/f1000research.25141.1 Text en Copyright: © 2020 Eddy JA et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Software Tool Article
Eddy, James A.
Thorsson, Vésteinn
Lamb, Andrew E.
Gibbs, David L.
Heimann, Carolina
Yu, Jia Xin
Chung, Verena
Chae, Yooree
Dang, Kristen
Vincent, Benjamin G.
Shmulevich, Ilya
Guinney, Justin
CRI iAtlas: an interactive portal for immuno-oncology research
title CRI iAtlas: an interactive portal for immuno-oncology research
title_full CRI iAtlas: an interactive portal for immuno-oncology research
title_fullStr CRI iAtlas: an interactive portal for immuno-oncology research
title_full_unstemmed CRI iAtlas: an interactive portal for immuno-oncology research
title_short CRI iAtlas: an interactive portal for immuno-oncology research
title_sort cri iatlas: an interactive portal for immuno-oncology research
topic Software Tool Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658727/
https://www.ncbi.nlm.nih.gov/pubmed/33214875
http://dx.doi.org/10.12688/f1000research.25141.1
work_keys_str_mv AT eddyjamesa criiatlasaninteractiveportalforimmunooncologyresearch
AT thorssonvesteinn criiatlasaninteractiveportalforimmunooncologyresearch
AT lambandrewe criiatlasaninteractiveportalforimmunooncologyresearch
AT gibbsdavidl criiatlasaninteractiveportalforimmunooncologyresearch
AT heimanncarolina criiatlasaninteractiveportalforimmunooncologyresearch
AT yujiaxin criiatlasaninteractiveportalforimmunooncologyresearch
AT chungverena criiatlasaninteractiveportalforimmunooncologyresearch
AT chaeyooree criiatlasaninteractiveportalforimmunooncologyresearch
AT dangkristen criiatlasaninteractiveportalforimmunooncologyresearch
AT vincentbenjaming criiatlasaninteractiveportalforimmunooncologyresearch
AT shmulevichilya criiatlasaninteractiveportalforimmunooncologyresearch
AT guinneyjustin criiatlasaninteractiveportalforimmunooncologyresearch